logo

Biotech Daily Dose

Share

pharmadown-sept19.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Thursday.

pharmaup-sept19.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-sept18.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.

pharmaup-sept18.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-041917_18sep19.jpg Today's Daily Dose brings you news about Bankruptcy filing of Sienna Biopharma; the first approval under FDA's Project Orbis, and public offering of Translate Bio.

pharmadown-sept17.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

pharmaup-sept17.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-050317_17sep19.jpg Today's Daily Dose brings you news about Acceleron Pharma pulling the plug on facioscapulohumeral muscular dystrophy trial; Aclaris Therapeutics' THWART-2 trial results; the $150 million investment by HealthCare Royalty Partners in Karyopharm and the upcoming regulatory catalyst of Seattle Genetics.

pharmadown-sept16.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

pharmaup-sept16.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-062617_14sep19.jpg The week ending September 14, 2019, witnessed a string of disappointments on the Alzheimer's drug development front. Now, here are some of the pharma/biotech stocks to watch out for in the week starting September 15.

pharmadown-sept12.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Thursday.

pharmaup-sept12.jpg The following are some of today's top gainers in the pharma/biotech sector.

anaptysbio-april12.jpg The FDA's Allergenic Products Advisory Committee, or APAC, is slated to determine whether or not to recommend approval of Palforzia, an experimental peanut allergy drug, developed by Aimmune Therapeutics Inc. (AIMT), on September 13, 2019.

pharmadown-sept10.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

Follow RTT